

Special Issue

The Role of Vaccines in Antimicrobial Stewardship Program to Reduce Resistance

Message from the Guest Editor

antimicrobial resistance (AMR) represents an emerging threat to global health, typically associated with high morbidity and mortality rate. According to a recent English report, if AMR is not controlled, 10 million people will die of drug-resistant bacterial infections annually in 2050 worldwide, with a cumulative economic loss reaching \$100 trillion. Despite vaccines are in a phase of major improvements and technological advances on many fronts, few attention has been paid to vaccines as a new element of antimicrobial stewardship programmes, yet the positive effect in reducing AMR has been well established. Therefore, the objective of this special issue is to look at how vaccines may be used in the fight against AMR, both directly, by reducing the incidence of bacterial infections, and indirectly, by the multiple ways in which they can reduce the use of antibiotics.

Guest Editor

Prof. Dr. Matteo Bassetti

1. Department of Health Sciences, University of Genoa, 16126 Genoa, Italy
2. Clinica Malattie Infettive, Ospedale Policlinico San Martino-IRCCS, 16132 Genoa, Italy

Deadline for manuscript submissions

closed (31 January 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/38898

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).